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245 A 10-year retrospective study of cystic ﬁbrosis patients with
distal intestinal obstruction syndrome (DIOS)
M.E.B. FitzPatrick1, D. Bilton1, F. Perrin2, D. Westaby3, N.J. Simmonds1. 1Royal
Brompton Hospital, Department of Cystic Fibrosis, London, United Kingdom;
2King’s College Hospital, Department of Cystic Fibrosis, London, United Kingdom;
3Hammersmith Hospital, Imperial College Healthcare NHS Trust, Department of
Gastroenterology, London, United Kingdom
Objectives: To describe our experience of DIOS management in an adult CF centre
over the past 10 years.
Methods: We assessed all cases of DIOS between 2002 and 2012 as captured by
electronic patient records and UK registry data. We reviewed imaging to ensure
episodes of DIOS met strict criteria.
Results: 37 patients (mean age 35 yrs, SD 12.0; 21 male) had 47 episodes of
DIOS, an annual incidence of 0.85%. 56% (19/34) were DF508 homozygous and
35% (12/34) were DF508 heterozygous. All patients were on pancreatic enzymes.
Mean FEV1 was 56% (SD 31.0) and mean FVC was 74% (SD 27.2). Abdominal
CT was performed on 13 patients. Treatments included oral gastrografﬁn (88%),
“Kleen-Prep” (56%), macrogols (56%), N-acetyl cysteine (18%), phosphate and
gastrografﬁn enemas (26% and 12%). 62% received intravenous ﬂuids and 32%
a nasogastric tube. Colonoscopy with gastrografﬁn instillation was performed
for 6 patients (13%). 1 patient required 2 colonoscopies, then was treated with
neostigmine with excellent effect. 2 patients presented at other hospitals and
underwent surgery. On discharge 89% received macrogol laxatives and 37% oral
gastrografﬁn. 1 patient was discharged on prucalopride with good effect. No patients
died during their admission. Comparison with 37 age and sex matched CF controls
showed more DIOS patients were pancreatic insufﬁcient (37 vs 27, p< 0.001) and
had a history of meconium ileus (12 vs 2, p< 0.01).
Conclusions: Our study shows the relatively low incidence of DIOS in adults. Most
cases were managed conservatively but 13% of patients required gastroenterology
input for colonoscopic therapy. Neostigmine and prucalopride may be considered
in highly selected cases.
246 High frequency of liver abnormalities in adult cystic ﬁbrosis
patients after lung transplantation
K. Staufer1, E. Halilbasic1, A. Niculescu1, S. Harm1, K. Rutter1, A. Brichta1,
P. Jaksch2, G. Murako¨zy2, E. Hielle-Wittmann2, W. Klepetko2, M. Trauner2,
L. Kazemi-Shirazi1. 1Medical University of Vienna, Internal Medicine III, Vienna,
Austria; 2Medical University of Vienna, Thoracic Surgery, Vienna, Austria
Background: CF associated liver disease (CFLD) mainly develops in early child-
hood and occurs in up to 30% of CF patients including features of steatosis, ﬁbrosis
and cholestasis. We aimed at characterizing liver disease in adult patients with CF
after lung transplantation (LuTx).
Methods: Consecutive patients admitted to our outpatient clinic received ultra-
sound, ﬁbroscan, MRI/MRCP as well as testing of liver function tests, lipids and
vitamin D. Liver diseases of other origins were excluded.
Results: 36 patients (median age 30 y, IQR 25−38 y; 42% male) were included in
the study. Median time since LuTx was 4.5 y (IQR: 2.3−8.3 y). Elevated AP/GGT
were found in 33%, elevated ALT/AST levels in 28% of patients. In 43% (12/23) of
patients steatosis and in 18% (4/23) either ﬁbrosis or liver cirrhosis was diagnosed
by ultrasound. In 39% (7/18) of patients MRI/MRCP revealed cholangiectasia, and
delayed excretion of contrast medium in 20% (3/15). Fibroscan proved cirrhosis in
2 patients, whereas in all other patients ﬁbrosis 0 to 1 was detected. No association
of liver function tests and results of imaging was found. Steatosis was signiﬁcantly
associated with hypertriglyceridemia (p< 0.05), but not with hypercholesterolemia.
Vitamin D levels in general were low. However, neither an association of vitamin D,
nor gender or BMI with liver disease was evident.
Conclusion: About 40% of post transplant patients show bile duct alterations sug-
gesting presence of CFLD. Hepatic steatosis associated with hypertriglyceridemia
is a common ﬁnding in adult CF patients after LuTx. Liver function tests seem to
be a weak parameter for monitoring liver disease in CF patients.
247 Diagnoses of cystic ﬁbrosis liver disease in an adult cystic
ﬁbrosis centre
C. Addy1, K. Bateman1, N.J. Bell1. 1Bristol Adult Cystic Fibrosis Centre, Bristol,
United Kingdom
Objectives: Estimates of the prevalence of Cystic Fibrosis Liver Disease (CFLD)
vary, diagnosis commonly being made in adolescence. Diagnosis is based on
physical examination, persistent abnormality of liver function tests (LFTs), and
ultrasound scan (USS) abnormality. The role of ultrasound to detect early CFLD is
questioned, as is the use of ursodeoxycholic acid (UDCA). We reviewed diagnoses
of CFLD in our adult CF centre.
Methods: Retrospective review of patient notes and electronic records (from
previous ﬁve years) of 126 people over 17 years who attend Bristol Adult CF Centre.
87% of patients had abnormal LFTs, with 27% having persistent abnormalities.
Rises in transaminases and alkaline phosphatase were equally common with
hyperbilirubinaemia seen in <15% patients.
31% had an abnormal USS, 65% of these showing fatty liver. Of 43 patients
identiﬁed as having “known” CFLD, 20 had a normal liver USS and 12 had
parenchymal disease or overt cirrhotic change. Splenomegaly was seen in only
3 patients. 10% did not attend for USS. 11% of those with normal LFTs had an
abnormal USS, and 71% with abnormal LFTs had a normal USS.
UDCA doses ranged from 250mg to 750mg, with no correlation between dose and
weight.
9 patients underwent Fibroscan™ liver elastography. 15 patients had endoscopy (for
various indications), 3 being found to have oesophageal varices.
Conclusion: This review conﬁrmed previous ﬁndings of poor correlation between
liver function, USS abnormalities, existing diagnoses of “CF liver disease”, OGD
or elastography ﬁndings and dosing of UDCA. We plan to investigate the role of
liver elastography in rationalising investigations in CF liver disease.
248 Evaluation of the clinical picture, considering liver lesions in
infants with cystic ﬁbrosis diagnosed during newborn screening
S. Wiecek1, H. Wos1, B. Kordys-Darmolinska1, U. Grzybowska-Chlebowczyk1.
1Medical University of Silesia, Department of Paediatrics, Katowice, Poland
The aim of the study was to evaluate the relationship between the genotype,
clinical picture and features of liver damage in infants with cystic ﬁbrosis (CF)
diagnosed during newborn screening.
Patients and Methods: The analysis involved 42 children, aged from 2 to 6 months,
in whom CF was diagnosed on the basis of screening tests. The analysis included:
genotype, birth weight, Apgar score, clinical symptoms, parameters of pancreatic
exocrine function, markers of liver damage and cholestasis, and abdominal ultra-
sound abnormalities. The obtained results were statistically analysed.
Results: The most common mutations of CFTR gene observed in infants
with diagnosed CF were: mutation delF508 − 36/42 − 85.7% [homozygotes
delF508/delF508 − 13/42 − 30.9% − heterozygotes delF508/other mutations 23/42 −
54.7%) and 1717−1G/A/2143delT in 2/42. The clinical picture was dominated by
respiratory symptoms (16/42) and/or body mass deﬁciency (9/42). In 24/42 infants
elevated acid steatocrit in faeces was detected. No statistically signiﬁcant differences
were observed between clinical symptoms, the birth weight, the birth Apgar score
and mutation of CFTR gene. Increased aminotransferase activity was observed in
10/42 infants, whereas GGTP in 15/42. In 7/42 children the abdominal ultrasound
revealed hepatic abnormalities, most often in the form of liver enlargement and/or
increased echogenicity.
Conclusion: Features of liver damage and/or cholestasis were observed even in
the youngest patients with diagnosed cystic ﬁbrosis. Mutation delF508 was the
most common abnormality of the genotype, which could have some impact on the
manifestation of hepatic abnormalities.
